Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy

Grégoire Justeau,Eric Huchot, Yannick Simonneau,Magali Roa,Jacques Le Treut,Gwenaelle Le Garff,Olivier Bylicki,Roland Schott, Anne-Sophie Bravard,Marie Tiercin,Régine Lamy, Gonzague De Chabot, Adina Marty, Diane Moreau,Chrystèle Locher, Cyril Bernier,Christos Chouaid,Renaud Descourt

Lung Cancer（2022）

引用 5|浏览5

暂无评分

摘要

•In 681 non-squamous aNSCLC PD-L1 ≥ 50 % patients, 12.5 % had a KRAS G12C mutation.•No clinical or biological difference between KRAS G12C and KRAS non-G12C patients.•KRAS G12C had no impact on first-line pembrolizumab efficacy in non-squamous aNSCLC.

查看译文

关键词

Non-small cell lung cancer,Metastatic disease,Pembrolizumab,KRAS mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要